AstraZeneca antibody works to prevent, treat COVID-19 in longer-term studies

AstraZeneca said on Thursday its COVID-19 antibody drug cocktail cut the risk of contracting symptomatic illness by 83% in a long-term follow-up, while the therapy also cut the risk of symptoms worsening when given within three days of first sympt...

By Reuters | Updated: Nov 18, 2021, 01.37 PM IST

AstraZeneca said on Thursday its COVID-19 antibody drug cocktail cut the risk of contracting symptomatic illness by 83% in a long-term follow-up, while the therapy also cut the risk of symptoms worsening when given within three days of first symptoms.

Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.